Pfizer expects to nearly cut in half the amount of time it takes to produce a batch of COVID-19 vaccine from 110 days to an average of 60 as it makes the process more efficient and production is built out, the company told USA TODAY.
As the nation revs up its vaccination programs, the increase could help relieve bottlenecks caused by vaccine shortages.
“We call this ‘Project Light Speed,’ and it’s called that for a reason,” said Chaz Calitri, Pfizer’s vice president for operations for sterile injectables, who runs the company’s plant in Kalamazoo, Michigan. “Just in the last month we’ve doubled output.”
The increased speed and capacity is not unexpected, said Robert Van Exan, president of Immunization Policy and Knowledge Translation, a vaccine production consulting firm.
“Nobody’s ever produced mRNA vaccines at this scale, so you can bet your bottom dollar the manufacturers are learning as they go. I bet you every day they run into some vaccine challenge and every day they solve it, and that goes into their playbook,” he said.
From DNA to doses:The COVID-19 vaccine life cycles
Pfizer’s COVID-19 vaccine is made at threePfizer plants: starting in Chesterfield, Missouri, moving to Andover, Massachusetts, and finishing in Kalamazoo, Michigan. As of Saturday, about 20.6 million doses of the Pfizer vaccine had been administered nationwide.
Pfizer based its production system on how the vaccine was developed in the laboratory, Calitri said. Normally engineers would spend years improving efficiencies and cost-effectiveness. That’s not what happened with COVID-19.
“We just went right to commercial production,” Calitri said.
As soon as vials of vaccine began coming off the production line, engineers started analyzing how production could work faster and better.
“We made a lot of really slick enhancements,” he said.
Production is getting faster. For example, making the DNA that starts the vaccine process first took 16 days; soon it will take nine or 10. Though quality control and testing has accelerated, company officials say FDA regulations and best manufacturing practices are still being met.
Along with improving speed, Pfizer also is increasing output by adding manufacturing lines in all three plants.
As the vaccine effort continues, more efficiencies are expected.
“There are going to be profound shifts in the way we do business,” Calitri said of what he’s experienced since his boss first called him on March 20, 2020 and said the Kalamazoo plant would play a key role in the rapid production of the vaccine.
“We just demonstrated to ourselves that we can go from a phone call in March to having now delivered 50 to 60 million doses.”
Contact Elizabeth Weise at email@example.com